Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-048001/1087	Application No. 10/684,212
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Lin Zhi *et al.*	
		Filing Date October 10, 2003	Group Art Unit 1625
(37 CFR §1.98(b))			

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
CA	AA	20040147530	10/10/03	Zhi et al.	514	256	10/10/03
CA	AB	20040152718	08/05/04	Zhi et al.	514	285	10/10/03
CA	AC	5,506,102	04/09/96	McDonnell et al.	435	6	10/28/93
CA	AD	5,994,544	11/30/99	Jones et al.	546	62	10/08/97
CA	AE	6,093,826	07/25/00	Edwards et al.	546	62	06/08/98
CA	AF	6,268,497	07/31/01	Edwards et al.	546	62	04/12/00
CA	AG	6,380,207	04/30/02	Coghlan et al.	514	285	02/13/98
CA	AH	6,448,405	09/10/02	Jones et al.	546	62	10/08/97
CA	AI	6,506,766	01/14/03	Coghlan et al.	514	285	07/05/00
CA	AJ	6,696,459	02/24/04	Jones et al.	514	285	10/14/97

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
CA	AK	200202565	06/27/01	PCT				
CA	AL	2004033459	04/22/04	PCT				
CA	AM	2004033460	04/22/04	PCT				
CA	AN	2004033461	04/22/04	PCT				
CA	AO	9619458	06/27/96	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CA	AP	Clemm et al., "Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor," Journal of Steroid Biochemistry and Molecular Biology 53(1-6):487-495. (1995)
CA	AQ	Edwards et al., "5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents," Journal of Medicinal Chemistry. 41(3):303-310 (1998)
CA	AR	Edwards et al., "Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists," Journal of Medicinal Chemistry 41(15):2779-2785 (1998)

Examiner Signature	Date Considered
ALAKM	10-4-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Mailed August 17, 2005

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-048001/1087	Application No. 10/684,212
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Lin Zhi *et al.*	
		Filing Date October 10, 2003	Group Art Unit 1625
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CA	AS	Hamann et al., "Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines," Bioorganic & Medicinal Chemistry Letters 8(19):2731-2736 (1998)
CA	AT	McDonnell et al., "Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors," Seminars in Cancer Biology, 5(5):327-336 (1994)
CA	AU	Miner, J. N. and C.M. Tyree, "Drug discovery and the intracellular receptor family," Vitamins and Hormones. 62:253-280. (2001)
CA	AV	Rosen et al., "Intracellular receptors and signal transducers and activators of transcription superfamilies - novel targets for small-molecule drug discovery," Journal of Medicinal Chemistry 38(25):4855-4874 (1995)
CA	AW	Santiso-Mere, D. and D.P. McDonnell, "Applied nuclear receptor research in the drug discovery process," Chimica Oggi. 12(5-6):29-36. (1994)
CA	AX	Silverman, R.B., "Prodrugs and Drug Delivery Systems," Chapter 8 in The Organic Chemistry of Drug Design and Drug Action, San Diego: Academic Press, Inc., pp. 352-401 (1992)
CA	AY	Tegley et al., "5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists," Journal of Medicinal Chemistry. 41(22):4354-4359. (1998)
CA	AZ	Vegeto et al., "Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function," Molecular Endocrinology. 7(10):1244-1255. (1993)
CA	BA	Wagner et al., "The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins," Endocrinology 140(3):1449-1458 (1999)
CA	BB	Wen et al., "The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells," Molecular and Cellular Biology 14(12):8356-8364 (1994)
CA	BC	Zhi, L. and K.B. Marschke, "Novel class of non-steroidal progesterone receptor antagonists," Expert Opinion on Therapeutic Patents. 9(6):695-700 (1999)
CA	BD	Zhi et al., "5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators," Bioorganic & Medicinal Chemistry Letters 8(23):3365-3370 (1998)
CA	BE	Zhi, et al. "Synthesis and Biological Activity of 5-Methylidine 1,2-Dihydrochromeno[3,4-f]quinoline Derivatives as Progesterone Receptor Modulators" Bioorganic & Medicinal Chemistry Letters 13:2071-2074 (2003).
CA	BF	Zhi et al., "5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists," Journal of Medicinal Chemistry 41(3):291-302 (1998)
CA	BG	Zhi et al., "5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification," Journal of Medicinal Chemistry. 42(8):1466-1472 (1999)
CA	BH	Zhi et al., "5-Benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as Selective Progesterone Receptor Modulators," Journal of Medicinal Chemistry 46(19):4104-4112 (2003)

Examiner Signature	AU/AXM	Date Considered	10-4-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Mailed August 17, 2005